Wen Lu

Wen Lu

Auto-generated profile, based on publicly available information

Wen Lu

Mayo Clinic Rochester Minnesota USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
VRVimal Ramjee
Vimal Ramjee
DLDeqiang Li
Deqiang Li
LMLauren J. Manderfield
Lauren J. Manderfield
FLFeiyan Liu
Feiyan Liu
KEKurt A. Engleka
Kurt A. Engleka
JEJonathan A. Epstein
Jonathan A. Epstein
Ischemic heart disease resulting from myocardial infarction (MI) is the most prevalent form of heart disease in the United States. Post-MI cardiac remodeling is a multifaceted process that includes activation of fibroblasts and a complex immune response. T-regulatory cells (Tregs), a subset of CD4+ T cells, have been shown to suppress the innate and adaptive immune response and limit deleterious remodeling following myocardial injury. However, the mechanisms by which injured myocardium recruits suppressive immune cells remain largely unknown. Here, we have shown a role for Hippo signaling in the epicardium in suppressing the post-infarct inflammatory response through recruitment of Tregs. Mice deficient in epicardial YAP and TAZ, two core Hippo pathway effectors, developed profound post-MI pericardial inflammation and myocardial fibrosis, resulting in cardiomyopathy and death. Mutant mice exhibited fewer suppressive Tregs in the injured myocardium and decreased expression of the gene encoding IFN-γ, a known Treg inducer. Furthermore, controlled local delivery of IFN-γ following MI rescued Treg infiltration into the injured myocardium of YAP/TAZ mutants and decreased fibrosis. Collectively, these results suggest that epicardial Hippo signaling plays a key role in adaptive immune regulation during the post-MI recovery phase.

6 February 2025 in Molecular Therapy
Verified
Journal Article
Open access
WLWen Lu
Wen Lu
JAJulie Allickson
Julie Allickson
In clinical trials, mesenchymal stromal/stem cells (MSC) have consistently demonstrated safety. However, demonstration of efficacy has been inconsistent and many MSC trials have failed to meet their efficacy endpoint. This disappointing reality is reflected by the limited number MSC therapies approved by regulatory agencies, despite the large number of MSC trials registered on clinicaltrials.gov. Notably, there has been a recent approval of an MSC therapy for pediatric graft-versus-host disease in the United States, marking the first MSC therapy approved by the Food and Drug Administration. This review provides background on the history and potential therapeutic value of MSC, an overview of MSC products with regulatory approval, and a summary of registered MSC trials. It concludes with a discussion on current and ongoing challenges and questions surrounding MSC therapy that remains to be resolved before becoming available for routine clinical use outside of clinical trials.

23 January 2020 in F1000Research
Verified
Journal Article
Open access
PDF file
WLWen Lu
Wen Lu
MFMark Fung
Mark Fung
Allogeneic platelets collected for transfusion treated with pathogen reduction technology (PRT), which has been available in some countries for more than a decade, are now increasingly available in the United States (US). The implementation of PRT-treated platelets, also known as pathogen-reduced platelets (PRPs), has been spurred by the need to further decrease the risk of sepsis associated with bacterial contamination coupled with the potential of this technology to reduce the risk of infections due to already recognized, new, and emerging infectious agents. This article will review available PRP products, examine their benefits, highlight unresolved questions surrounding this technology, and summarize pivotal research studies that have compared transfusion outcomes (largely in adult patients) for PRPs with non-PRT-treated conventional platelets (CPs). In addition, studies describing the use of PRPs in pediatric patients and work done on the association between PRPs and HLA alloimmunization are discussed. As new data emerge, it is critical to re-evaluate the risks and benefits of existing PRPs and newer technologies and reassess the financial implications of adopting PRPs to guide our decision-making process for the implementation of transfusing PRPs.

12 February 2021 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
PDF file
WLWen Lu
Wen Lu
WKWalter Kelley
Walter Kelley
DFDeanna C. Fang
Deanna C. Fang
SJSarita Joshi
Sarita Joshi
YKYoung Kim
Young Kim
HPHuy P. Pham
Huy P. Pham

15 July 2022 in Transfusion
Verified
Journal Article
Closed access
WLWen Lu
Wen Lu
MYMark Yazer
Mark Yazer
NLNa Li
Na Li
AZAlyssa Ziman
Alyssa Ziman
Silvano WendelSilvano Wendel
Silvano Wendel
BCBiomedical Excellence for Safer Transfusions Collaborative
Biomedical Excellence for Safer Transfusions Collaborative

2 July 2022 in Transfusion
Verified
Journal Article
Closed access
MCMischa L. Covington
Mischa L. Covington
JCJensyn K. Cone‐Sullivan
Jensyn K. Cone‐Sullivan
CAChester Andrzejewski
Chester Andrzejewski
WLWen Lu
Wen Lu
RTReggie R. Thomasson
Reggie R. Thomasson
SSSean R. Stowell
Sean R. Stowell